Navigation Links
New strategy produces promising advance in cancer vaccines

Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences (PNAS), Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells. The research suggests a method for developing vaccines against a wide variety of cancers.

"We developed a peptide vaccine that binds strongly to naturally occurring T cells and stimulates them to vigorously attack cancer cells in mice," said Dr. Slansky, Associate Professor in the Integrated Immunology Department at National Jewish Health and the University of Colorado School of Medicine. "We can't guarantee that the vaccines we developed will make it to human trials, but our work does show that very effective cancer vaccines can be made, and outlines a new strategy for their development."

T cells are one of the prime sentinels of the immune system, which sound the alarm and help orchestrate the immune response. Ever since scientists found T cells inside tumors, they realized that the body does have a natural, albeit mild, immunity to cancer. The T cells inside tumors recognize antigens on the surfaces of tumor cells, but don't bind them strongly enough to sound an alarm or initiate a robust immune response.

Scientists have tried several strategies to stimulate those T cells, from general immune stimulants to synthetic variations on the naturally occurring antigens. Although some of the vaccines showed moderate results in animal models, none has proven effective in humans.

Dr. Slansky hypothesized that previous vaccine candidates were unsuccessful because they did not bind strongly enough to the T cells found inside tumors. As a result, the vaccines failed to stimulate the T cells into mounting an effective immune response. So, she, structural biologist Dr. Kappler, and Dr. Kimberly Jordan, the postdoctoral fellow whose work bridges the two labs, designed peptide vaccines that resemble naturally occurring antigens but bind more strongly to the T cells found inside tumors.

They evaluated five candidate peptide vaccines. They vaccinated mice twice with the candidate vaccines, then injected colon tumor cells into the mice a week later. The results were quite variable. Two of the vaccines protected few or no mice, three other vaccines kept 60%, 90% and 100% alive and tumor-free for 60 days.

The researchers tried to learn what distinguished the effective peptide vaccines from ineffective ones. They found that the ineffective vaccines strongly stimulated T cells that recognized the peptide vaccine but not any T cells that recognized antigen on the cancer cells.

The successful vaccines stimulated T cells that recognized both the peptide vaccine and the naturally occurring antigen. The successful antigens stimulated the growth of many more T cells than the ineffective ones. Those T cells were also highly activated and ready to attack, as evidenced by their production of cytokine signaling molecules. Remarkably, the most successful vaccine varied by only one amino acid from the naturally occurring antigen, which provoked almost no immune response.

"Our theory about the importance of the T cellpeptide bond was correct, but we learned that the peptides must also stimulate T cells that cross react with the existing antigens and produce a large population of activated T cells," said Dr. Kappler. "We believe this provides a very promising strategy for developing cancer vaccines. We are now working to learn why a single-amino-acid substitution makes such a huge difference in effectiveness."


Contact: Adam Dormuth
National Jewish Medical and Research Center

Related medicine news :

1. AWT Management Announce Aggressive Growth and Acquisition Strategy
2. Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer
3. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
4. More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States
5. Penn Veterinary Medicine report new strategy to create genetically modified animals
6. Novel strategy under study for aggressive leukemia
7. AIDS Action Council Commends Senator Edwards for Endorsing a National HIV/AIDS Strategy
8. Blue Shield of California Names Vincent Coppola Vice President of Strategy and Business Development
9. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
10. Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
11. Computerized training of working memory is a promising therapeutic strategy in ADHD
Post Your Comments:
(Date:10/12/2015)... NJ (PRWEB) , ... October 12, 2015 , ... The ... programs and initiatives focused on improving public health and enhancing the quality of life ... will go to 11 New Jersey non-profit organizations. , The charitable arm of ...
(Date:10/12/2015)... ... October 12, 2015 , ... Advera Health Analytics, Inc . ... qualified Managed Care Organizations (MCOs) in order to provide health plans, payers, systems, and ... making process. In addition, the DSM is also being offered to healthcare media organizations ...
(Date:10/12/2015)... ... October 12, 2015 , ... A new invention has just been ... An inventor from Rutland, Mass., has modified a conventional nasal aspirator with child safety ... in withdrawing mucus from sinuses and nasal passages more safely and effectively than with ...
(Date:10/12/2015)... , ... October 12, 2015 , ... NFL football fans who are interested in having ... a great cause. CLICK HERE to donate to Smile for a Lifetime (S4L) ... to win an all-inclusive trip to the 2016 NFL Super Bowl! , Donors contributing $20.00 ...
(Date:10/12/2015)... York, NY (PRWEB) , ... October 12, 2015 ... ... Inc., Care to Care has secured a new corporate headquarters, located at 485 ... will allow for improved workflow and increased emphasis on cloud-based technology. , “Care ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
(Date:10/12/2015)... St. Paul, Minn. , Oct. 12, 2015 /PRNewswire/ ... with it, a need to help integrate these devices ... global leader of ergonomic healthcare mounting and mobility solutions, ... Carts, its lightest cart yet, for a wide array ... StyleView S-Tablet Cart SV10 was developed exclusively for Microsoft ...
(Date:10/12/2015)... 12, 2015 ... grow at 7.2% CAGR, microscopy market growth ... focus on nanotechnology, technological advancements, and increasing ... available with ... --> Complete report on microscopy ...
Breaking Medicine Technology: